
Oral vaccine strategy used modified bacterium to combat colorectal cancer
A research team investigating the use of the bacterium Listeria monocytogenes against colorectal cancer has discovered a way to build a modified version of Listeria as an oral vaccine to prime the immune system directly within the gut, where anti-tumor cells are then generated. Details of the work, led by Stony Brook immunologist Brian Sheridan, Ph.D., are published in the Journal for the ImmunoTherapy of Cancer.








